Experts discuss sequencing and patient selection for radiopharmaceuticals in advanced prostate cancer
read at onclive ↗Neutral
Dr. Johann De Bono and Dr. Pedro Barata discuss how treatment sequencing is evolving for radiopharmaceuticals in metastatic castration-resistant prostate cancer.
They highlight the need to match patients to the appropriate radiopharmaceutical based on disease characteristics as more options become available.
The conversation is part of a multi-episode series that has covered radiopharmaceutical strategies, combination approaches, safety and future directions in mCRPC.
source
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer”
read at onclive ↗1,687 words · retrieved May 13
comments(0)
5-min edit window · permanent after that